Shares of National Research Corporation (NASDAQ:NRC - Get Free Report) passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $16.45 and traded as high as $17.60. National Research shares last traded at $17.11, with a volume of 112,562 shares trading hands.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings downgraded shares of National Research from a "hold (c-)" rating to a "sell (d+)" rating in a research note on Friday, March 6th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has an average rating of "Sell".
View Our Latest Analysis on National Research
National Research Price Performance
The stock has a market capitalization of $389.25 million, a price-to-earnings ratio of 34.22 and a beta of 0.39. The company has a quick ratio of 0.55, a current ratio of 0.55 and a debt-to-equity ratio of 5.36. The business's 50 day simple moving average is $16.03 and its 200-day simple moving average is $16.45.
National Research (NASDAQ:NRC - Get Free Report) last announced its quarterly earnings data on Tuesday, February 3rd. The company reported $0.16 earnings per share (EPS) for the quarter. The firm had revenue of $35.19 million for the quarter. National Research had a net margin of 8.44% and a return on equity of 103.84%.
Institutional Investors Weigh In On National Research
A number of large investors have recently bought and sold shares of the company. Hotchkis & Wiley Capital Management LLC grew its stake in National Research by 7.9% during the third quarter. Hotchkis & Wiley Capital Management LLC now owns 292,400 shares of the company's stock worth $3,737,000 after buying an additional 21,450 shares in the last quarter. AQR Capital Management LLC grew its stake in National Research by 86.2% during the second quarter. AQR Capital Management LLC now owns 201,396 shares of the company's stock worth $3,383,000 after buying an additional 93,262 shares in the last quarter. Willis Investment Counsel grew its stake in National Research by 1.6% during the fourth quarter. Willis Investment Counsel now owns 183,226 shares of the company's stock worth $3,439,000 after buying an additional 2,920 shares in the last quarter. Bank of America Corp DE boosted its stake in shares of National Research by 5.8% in the 2nd quarter. Bank of America Corp DE now owns 122,344 shares of the company's stock valued at $2,055,000 after purchasing an additional 6,690 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its stake in shares of National Research by 18.6% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 114,967 shares of the company's stock valued at $2,158,000 after purchasing an additional 18,067 shares in the last quarter. 47.26% of the stock is currently owned by institutional investors and hedge funds.
National Research Company Profile
(
Get Free Report)
National Research Corp NASDAQ: NRC, also known as NRC Health, is a healthcare analytics and performance improvement company specializing in patient and employee experience measurement. The company's cloud-based platform enables healthcare providers to collect real-time feedback through patient satisfaction surveys, post-discharge outreach, and employee engagement tools. NRC Health integrates clinical, operational and financial data to deliver actionable insights that support quality improvement initiatives and value-based care programs.
Since its founding in the early 1990s and headquartered in Lincoln, Nebraska, National Research has expanded beyond its regional roots to serve more than 1,600 hospitals and 12,000 care sites across the United States and Canada.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider National Research, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and National Research wasn't on the list.
While National Research currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.